Log In
Print
BCIQ
Print
Print this Print this
 

Treximet, sumatriptan/naproxen

Also known as: formerly Trexima

  Manage Alerts
Collapse Summary General Information
Company Pozen Inc.
DescriptionCombination of sumatriptan and naproxen sodium
Molecular Target Serotonin (5-HT1B) receptor ; Serotonin (5-HT1D) receptor
Mechanism of ActionSerotonin (5-HT1B) receptor agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat acute migraine, with or without aura, in adults; Treat migraine in adolescents; Treat migraine in patients with a poor response or intolerance to short-acting triptan treatment; Treat probable migraine
Regulatory Designation

U.S. - Priority Review (Treat migraine in adolescents)

Partner

GlaxoSmithKline plc; Pernix Therapeutics Holdings Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$325.0M

$325.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today